# A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

Study · id `cardio:ct-nct05975905` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05975905](<https://clinicaltrials.gov/study/NCT05975905>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05975905

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 113 participants.

## Technical summary

Registry record NCT05975905. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-17 (actual); primary completion 2025-03-05 (actual). Results posted on 2026-07-02.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 113 participants (enrolled count; ClinicalTrials.gov record NCT05975905, source copy `cardio:ctgov-nct05975905-2026-07-02`, retrieved 2026-10-31)
- Started: 2023-10-17 (actual) (ClinicalTrials.gov record NCT05975905, source copy `cardio:ctgov-nct05975905-2026-07-02`, retrieved 2026-10-31)
- Primary completion: 2025-03-05 (actual) (ClinicalTrials.gov record NCT05975905, source copy `cardio:ctgov-nct05975905-2026-07-02`, retrieved 2026-10-31)
- Completion: 2025-03-11 (actual) (ClinicalTrials.gov record NCT05975905, source copy `cardio:ctgov-nct05975905-2026-07-02`, retrieved 2026-10-31)
- Results first posted: 2026-07-02 (ClinicalTrials.gov record NCT05975905, source copy `cardio:ctgov-nct05975905-2026-07-02`, retrieved 2026-10-31)
- Countries: United States; Australia; Brazil; France; Germany; Poland; Portugal; South Korea; Spain; Taiwan; United Kingdom (ClinicalTrials.gov record NCT05975905, source copy `cardio:ctgov-nct05975905-2026-07-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05975905-2026-07-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).
- Condition: Pulmonary Arterial Hypertension
- Intervention (Biological): Dose A KER-012
- Intervention (Biological): Dose B KER-012
- Intervention (Biological): Dose C KER-012
- Intervention (Biological): Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks
- Lead sponsor: Keros Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 73862684713982d758267d3d1083c844ec3115e4293b263e12bd4e051c7dd545
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
